Department of Neurology, Tohoku University Graduate School of Medicine, Sendai, Japan; Department of Education and Support for Regional Medicine, Tohoku University Hospital, Sendai, Japan.
Department of Neurology, Tohoku University Graduate School of Medicine, Sendai, Japan; Department of Neurology, National Hospital Organization Yonezawa National Hospital, Yonezawa, Japan.
J Neuroimmunol. 2020 Mar 15;340:577168. doi: 10.1016/j.jneuroim.2020.577168. Epub 2020 Jan 23.
We aimed in this study to elucidate the impact of serum AQP4-IgG titer before starting treatments to the clinical manifestation of neuromyelitis optica spectrum disorders (NMOSD). Serum titer at the onset, measured using live cell-based assay method, did not correlate to the subsequent relapse rate or neurological prognosis. Patients with optic neuritis as the first attack showed significantly higher serum titer than patients with acute myelitis or area postrema syndrome, although the titer did not correlate to the visual prognosis. The result implies that the pathological mechanism of optic neuritis and acute myelitis could be different in NMOSD.
本研究旨在阐明开始治疗前血清 AQP4-IgG 滴度对视神经脊髓炎谱系疾病（NMOSD）临床表现的影响。使用活细胞检测方法测量的发病时血清滴度与随后的复发率或神经预后无关。首发为视神经炎的患者血清滴度明显高于急性脊髓炎或延髓后区综合征患者，尽管滴度与视力预后无关。结果表明 NMOSD 中视神经炎和急性脊髓炎的病理机制可能不同。
